RBC Capital sets Insulet stock Outperform with $340 price target

On Thursday, RBC Capital Markets began coverage on Insulet Corporation (NASDAQ:PODD), a medical device company known for its tubeless insulin pump technology. The firm assigned an Outperform rating to the company’s shares, coupled with an ambitious price target of $340.00. According to InvestingPro data, the stock has demonstrated remarkable performance with a 63% return over the past year, trading near its 52-week high of $289.46.

RBC Capital’s assessment is based on Insulet’s unique position in the market as the provider of the only patch automated insulin delivery (AID) system currently available. This innovation, along with several strategic advantages such as being a first mover, its product’s form factor, and pharmacy access, sets Insulet apart in the competitive landscape. The company’s strong market position is reflected in its impressive financial metrics, with InvestingPro reporting a robust gross profit margin of nearly 70% and revenue growth of 22% in the last twelve months.

According to RBC Capital, conversations with Key Opinion Leaders (KOLs) reveal that there is potential for growth beyond the market’s current expectations. This optimism is fueled by several factors, including the widespread adoption of Insulet’s Omnipod 5 AID system, opportunities to convert multiple daily injection (MDI) users, the potential for expanded use in Type 2 diabetes, ongoing geographic expansion, and the integration with continuous glucose monitoring (CGM) systems. The company’s strong financial health score of "GREAT" from InvestingPro, along with its comfortable current ratio of 3.58, suggests it’s well-positioned to execute on these growth opportunities.

The analysts at RBC Capital also project that Insulet will experience an annual margin expansion of at least 100 basis points. This improvement is expected to drive an impressive 26% growth in earnings per share (EPS) over the next three years, which in turn could lead to an increase in the company’s stock price. With a market capitalization of $19 billion and trading at a P/E ratio of 45, investors seeking deeper insights can access comprehensive analysis and 14 additional ProTips through InvestingPro’s detailed research report.

The firm’s statement highlighted the key drivers behind the initiation of coverage, "Our KOL checks suggest upside to consensus/ RBC growth estimates driven by global Omnipod 5 AID adoption aided by significant MDI conversion opportunity, Type 2 indication expansion, geographic expansion, and CGM integration. Further, we see at least 100bps of annual margin expansion driving +26% EPS growth over the next three years and the stock higher. As such, we are initiating at Outperform/$340 PT."

In other recent news, Insulet Corporation reported notable financial achievements for the fourth quarter of 2024, with revenue reaching $597.5 million, marking a 17% increase year-over-year. This performance exceeded expectations, with earnings per share (EPS) reported at $1.15, surpassing the forecast of $1.03. Analysts from Canaccord Genuity, BTIG, and Bernstein have all raised their price targets for Insulet, reflecting confidence in the company’s future growth prospects. Canaccord Genuity set a new target of $324, BTIG increased theirs to $310, and Bernstein adjusted theirs to $335, each maintaining positive ratings on the stock.

Additionally, Insulet’s international revenue saw significant growth, with a 33.1% increase on a constant currency basis, driven by strong demand for the Omnipod system. The company has been expanding its market presence, particularly among Type 2 diabetes patients, who now account for over 30% of new U.S. prescriptions. Stifel analysts, however, maintained a Hold rating with a price target of $293, citing a cautious outlook for the first quarter of 2025.

Insulet’s strategic focus on expanding its sales force and increasing prescriber engagement for Type 2 diabetes is expected to drive further growth. The company also announced an investor day scheduled for June 5, 2025, to provide more insights into its strategic direction and financial outlook. These developments highlight Insulet’s ongoing efforts to capitalize on market opportunities and enhance its competitive position in the diabetes management sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.